Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. - Wikidata - wikimedia - TriplyDB

Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.

Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.

http://www.wikidata.org/entity/Q35161856

about

Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.EMT and inflammation: inseparable actors of cancer progression.Metformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress.Diabetes, pancreatic cancer, and metformin therapy.Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition.Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 up-regulation The impact of metformin and salinomycin on transforming growth factor β-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines IL-17 induces EMT via Stat3 in lung adenocarcinoma Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.Metformin therapy associated with survival benefit in lung cancer patients with diabetes Metformin, an old drug, brings a new era to cancer therapy Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro.Complex I inhibition augments dichloroacetate cytotoxicity through enhancing oxidative stress in VM-M3 glioblastoma cells.Combinational strategies of metformin and chemotherapy in cancers.Effects of metformin treatment on glioma-induced brain edema.Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.The CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling.Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies.Gram-positive pneumonia augments non-small cell lung cancer metastasis via host toll-like receptor 2 activation.Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II.Suppressive effect of AMP-activated protein kinase on the epithelial-mesenchymal transition in retinal pigment epithelial cells.Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target.Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma.Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.IL-37 inhibits invasion and metastasis in non-small cell lung cancer by suppressing the IL-6/STAT3 signaling pathway.Metformin and berberine, two versatile drugs in treatment of common metabolic diseases.Metformin inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the phosphorylation of Akt.Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma USP24 induces IL-6 in tumor-associated microenvironment by stabilizing p300 and β-TrCP and promotes cancer malignancy

P2860

Q26741846-33F2B7E3-5352-412D-9B1F-6D99E5F5E707 Q26750845-F19D28A0-6144-4BB6-87FE-6EB6BC615DB5 Q33866151-69034B28-1E35-46D4-9231-96CD0AD5BD80 Q33869755-B47E1C34-F9B5-4C08-95E1-2A54E039FBB5 Q33915937-3D16707C-1539-4F6A-A7EC-697D1F30FCBF Q34471173-8E26295B-FC3B-43B7-8557-CDEEAB6A2503 Q35928957-17762F8C-602B-4BDB-9888-AC21DDE0A58D Q36316820-218CC67E-B761-4494-AE3D-7980513EF120 Q36562147-3D31EBA2-0BE1-42DF-BA1B-29A28ECA4FC5 Q36742179-77B3FB70-B1B6-46C9-A76A-543A0CDFA340 Q36878756-78FD47E7-D1FE-4D86-BF38-FCBC5955BC39 Q37118676-29129240-3202-4B47-90A1-7FA6730C3AFE Q37376577-FB953E1B-A164-457D-AAA8-AEFD93B1AEAD Q38393435-914D7303-46DD-4518-8012-C3B2580232CD Q38674016-85A7C418-39BA-4532-B114-D6272FA8C865 Q38711927-08912224-5299-47FB-BEA2-A33AD0B3D7E7 Q38818730-027B3E34-3C17-4C0B-B980-C86E1CE78677 Q38819549-5320CEB1-76CD-4D47-AF7E-867ECF1F37D7 Q38903138-8E2F7BA2-F012-46D5-BEB8-169C95C4868E Q38947635-6A57A94A-F29E-4F06-92A9-8A1CAEEBFE96 Q39057993-77A6E173-650A-41F2-8373-B8FFC70B0375 Q39290525-C346B822-3FD5-4770-B797-F6375D0D7B23 Q40254726-4150422E-A59F-4128-8592-B99C3A03E06F Q40989059-C7D9F9B7-1480-4CEC-A6C0-F5CA502884F5 Q41047846-63348EAF-F6CD-447F-A92E-156AA32A1941 Q41809872-346BA9F6-B727-494A-85F3-0ABD2EFAAE9A Q47575075-3AB1CF03-30BB-4EE6-B149-296761931F60 Q48514273-FFC3E987-D5C8-4CE1-BC27-F17756804C40 Q51748677-EB25D6C7-7932-46CB-BBDF-CFAC786FAA68 Q52633205-5C26874E-FE7A-475B-B5B0-30675E70095B Q52668163-7846A4F6-16B7-426E-8D57-0FF32ADB595A Q54221394-07BC1289-A50A-403B-A9E4-79CD6085C6C9 Q57132035-FAD5BEAF-6416-4E99-A240-58B843DF9626 Q58696594-80ACDEB2-CA4D-4B84-9293-4B01FA8FAC73 Q59126271-0F5ED899-7357-4D33-9653-8D1FBC5704E7

P2860

Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.

http://www.wikidata.org/entity/Q35161856

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Metformin inhibits the IL-6-in ...... rcinoma growth and metastasis.

@ast

Metformin inhibits the IL-6-in ...... rcinoma growth and metastasis.

@en

type

label

Metformin inhibits the IL-6-in ...... rcinoma growth and metastasis.

@ast

Metformin inhibits the IL-6-in ...... rcinoma growth and metastasis.

@en

prefLabel

Metformin inhibits the IL-6-in ...... rcinoma growth and metastasis.

@ast

Metformin inhibits the IL-6-in ...... rcinoma growth and metastasis.

@en

P1433

Q35161856-D22D2C14-A6AE-4A1F-8DBC-0C5895FDC37A

P1476

Q35161856-180CDA96-7DB8-4D77-80AC-F9E2352C9B29

P2093

Q35161856-0D65D1BA-0E1E-4196-91FA-A0989595FA7C

Q35161856-1700DFF2-D67C-445D-B0E8-8E8FECE00A79

Q35161856-2424C57F-837D-4CF2-B32B-944B006BB6AD

Q35161856-363A42E4-33DC-4725-94EB-628D5D977314

Q35161856-4AFBC490-B87A-4846-9550-EAE45B4ADC03

Q35161856-93AE846C-3682-48AD-ABC4-CC147C33A114

Q35161856-A2000306-4BF4-46C6-998E-A3BD5A127DAE

Q35161856-B06A3B74-5603-4043-8DD3-D9BE47B7D7CF

Q35161856-C9B1C8B8-DAD8-454F-957D-F4C39158AA45

Q35161856-F149474D-1989-4708-B5CC-C3AA8A28BA0C

P2860

Q35161856-001F7935-7022-4DC7-B0B7-2ED15BF355DF

Q35161856-00F00B7E-7FCD-49DC-A66D-247E1588891E

Q35161856-07DD28A1-A28B-45CD-A04B-FEA40362249B

Q35161856-0CC08B10-DD25-4056-9FC5-C71AF36F774D

Q35161856-0DFAF887-63EC-4BE5-BCB6-D578A74E195E

Q35161856-20879946-806C-4821-B615-8F7A114B66E7

Q35161856-214D8932-A167-4D1B-8126-5A94F6A9090D

Q35161856-2E832464-DF93-4879-9B9E-6CC152297FA2

Q35161856-309B73C5-78BB-46EE-8266-E4A96AB66885

Q35161856-31D5F08F-FBE9-4229-A9A6-FE5C5C391575

P304

Q35161856-AAED526B-DC4F-4117-8F2A-07A0D0C38B48

P31

Q35161856-1DB1D4A6-967A-4EB1-86E9-28F832617C73

P356

Q35161856-FD9063B6-6ABC-4EA8-BF1D-396ED5CEFA7F

P407

Q35161856-A41C02A3-5098-4EC2-9F00-5B27B308C658

P433

Q35161856-F4566DBA-2F20-47BB-8881-7F55F33DD226

P478

Q35161856-672F42FD-223D-4809-B231-1CD1E7C024A1

P577

Q35161856-4D948919-C844-4E47-A1C8-7FD0AE00F0FE

P5875

Q35161856-DB4540DC-154B-4903-92B1-37D71223A115

P698

Q35161856-C6E7E82B-D320-46DD-8785-E6857E9E1E30

P921

Q35161856-3E3FB553-3B06-4BB8-B6B4-A68103D5C089

Q35161856-90FD24AA-EEB0-40B0-9D41-37DF7A3CDED6

P932

Q35161856-02E5C267-39F4-4D44-BCB6-9697E5EC9C1A

P356

JOURNAL.PONE.0095884

P1433

P1476

Metformin inhibits the IL-6-in ...... rcinoma growth and metastasis.

@en

P2093

Bo Zhu

http://www.w3.org/2001/XMLSchema#string

Haixia Long

http://www.w3.org/2001/XMLSchema#string

Li Li

http://www.w3.org/2001/XMLSchema#string

Luhang He

http://www.w3.org/2001/XMLSchema#string

Rui Han

http://www.w3.org/2001/XMLSchema#string

Tong Xiang

http://www.w3.org/2001/XMLSchema#string

Xiaoming Cheng

http://www.w3.org/2001/XMLSchema#string

Yong He

http://www.w3.org/2001/XMLSchema#string

Yubo Wang

http://www.w3.org/2001/XMLSchema#string

Zhongquan Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

Epithelial-mesenchymal transitions in tumour progression

Epithelial-mesenchymal transitions in development and disease

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Cancer statistics, 2009

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression

Metformin and reduced risk of cancer in diabetic patients

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

P304

e95884

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0095884

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262024974

http://www.w3.org/2001/XMLSchema#string

P698

24789104

http://www.w3.org/2001/XMLSchema#string

P921

P932

4005743

http://www.w3.org/2001/XMLSchema#string